[go: up one dir, main page]

ATE320801T1 - Therapeutisches oder vorbeugendes mittel für glomerulopathie - Google Patents

Therapeutisches oder vorbeugendes mittel für glomerulopathie

Info

Publication number
ATE320801T1
ATE320801T1 AT98932574T AT98932574T ATE320801T1 AT E320801 T1 ATE320801 T1 AT E320801T1 AT 98932574 T AT98932574 T AT 98932574T AT 98932574 T AT98932574 T AT 98932574T AT E320801 T1 ATE320801 T1 AT E320801T1
Authority
AT
Austria
Prior art keywords
diyl
lower alkyl
thiophen
optionally substituted
phenyl
Prior art date
Application number
AT98932574T
Other languages
English (en)
Inventor
Hidetake Kurihara
Fumihiko Watanabe
Yoshinori Tamura
Toshihiro Sinosaki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE320801T1 publication Critical patent/ATE320801T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98932574T 1997-07-22 1998-07-17 Therapeutisches oder vorbeugendes mittel für glomerulopathie ATE320801T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19541497 1997-07-22

Publications (1)

Publication Number Publication Date
ATE320801T1 true ATE320801T1 (de) 2006-04-15

Family

ID=16340702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98932574T ATE320801T1 (de) 1997-07-22 1998-07-17 Therapeutisches oder vorbeugendes mittel für glomerulopathie

Country Status (21)

Country Link
US (2) US6423729B1 (de)
EP (2) EP1029541B1 (de)
JP (1) JP3621427B2 (de)
KR (1) KR100386148B1 (de)
CN (1) CN1198607C (de)
AT (1) ATE320801T1 (de)
AU (1) AU737218B2 (de)
BR (1) BR9811521A (de)
CA (1) CA2297011C (de)
DE (2) DE69833940T2 (de)
HU (1) HUP0003851A3 (de)
ID (2) ID29293A (de)
IL (1) IL133933A0 (de)
NO (1) NO20000285L (de)
NZ (1) NZ502274A (de)
PL (1) PL338235A1 (de)
RU (1) RU2207849C2 (de)
SK (1) SK262000A3 (de)
TR (2) TR200100389T2 (de)
TW (2) TW593249B (de)
WO (1) WO1999004780A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198607C (zh) * 1997-07-22 2005-04-27 盐野义制药株式会社 治疗或预防肾小球病的组合物
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
ID24957A (id) 1998-02-04 2000-08-31 Novartis Ag Turunan sulfonilamino yang menginhibisi metaloproteinase penurun matriks
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
US6495578B1 (en) 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
FR2798589B1 (fr) * 1999-09-16 2001-11-30 Oreal Composition cosmetique comprenant au moins un copolymere silicone/acrylate et au moins un agent epaississant
EP1270569A4 (de) 2000-01-26 2005-01-05 Shionogi & Co Substituierte tryptophanderivate
US7288567B2 (en) * 2000-03-24 2007-10-30 Methylgene Inc. Inhibitors of histone deacetylase
AU2001248765A1 (en) * 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
BR0110211A (pt) * 2000-04-21 2003-06-03 Shionogi & Co Derivados de oxadiazol tendo efeitos anticâncer
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
AU2001248820A1 (en) * 2000-04-28 2001-11-12 Shionogi And Co., Ltd. Thiazole and oxazole derivatives
AU2001292285A1 (en) 2000-09-29 2002-04-15 Shionogi And Co., Ltd. Thiazole or oxazole derivatives
WO2003031419A1 (en) 2001-10-09 2003-04-17 3-Dimensional Pharmaceuticals, Inc. Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
ATE438618T1 (de) * 2001-12-14 2009-08-15 Exelixis Inc Inhibitoren von humanem adam-10
NZ536189A (en) 2002-05-29 2007-08-31 Merck & Co Inc Methylphenylsulfonyl amide derivative compounds useful in the treatment of anthrax and inhibiting lethal factor
EP1650199A4 (de) 2003-07-30 2008-11-19 Shionogi & Co Sulfonamidderivat mit isoxazolring
US7504431B2 (en) * 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
CA2566191A1 (en) 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
JP2006036691A (ja) * 2004-07-27 2006-02-09 Shionogi & Co Ltd 腎炎の治療または予防剤
US20080119513A1 (en) * 2004-09-06 2008-05-22 Fumihiko Watanabe Sulfonamide Derivative Selectively Inhibiting Mmp-13
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
EP1997804A1 (de) 2006-03-03 2008-12-03 Shionogi & Co., Ltd. Mmp-13-selektiver inhibitor
WO2008053913A1 (en) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
RU2528333C2 (ru) * 2008-12-23 2014-09-10 Аквилус Фармасьютикалз, Инк Соединения и способы лечения боли и других заболеваний
EP3668856B1 (de) 2017-08-17 2021-06-23 GlaxoSmithKline Intellectual Property Development Limited Neue tetrazol verbindungen und ihre verwendung in der behandlung von tuberkulose

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
JP3818322B2 (ja) * 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
GB2303850B (en) 1994-06-22 1998-06-10 British Biotech Pharm Metalloproteinase inhibitors
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
KR19990036271A (ko) 1995-08-08 1999-05-25 토마스 네프 콜라겐 과다생산과 연관된 질환의 치료에 이용되는 ｃ-프로테나제 저해물질
ATE226936T1 (de) * 1995-08-08 2002-11-15 Ono Pharmaceutical Co Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
JPH09110864A (ja) * 1995-08-10 1997-04-28 Kureha Chem Ind Co Ltd クロモン誘導体、その製造方法及び医薬組成物
JPH0987178A (ja) 1995-09-22 1997-03-31 Toyama Chem Co Ltd 神経成長因子の作用増強剤
JPH0987176A (ja) 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
KR100338861B1 (ko) * 1996-01-23 2003-02-20 시오노기세이야쿠가부시키가이샤 술폰화아미노산유도체및이를함유한메탈로프로테이나제저해제
DE69707865T2 (de) 1996-05-17 2002-05-02 Warner-Lambert Co., Morris Plains Biphenylsulfonamid matrix metalloproteinase inhibitoren
JPH10265452A (ja) * 1996-05-24 1998-10-06 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
JP2000515153A (ja) * 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
JP2001521504A (ja) * 1997-04-01 2001-11-06 アグロン・ファーマシュウティカルズ・インコーポレーテッド メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用
CN1198607C (zh) * 1997-07-22 2005-04-27 盐野义制药株式会社 治疗或预防肾小球病的组合物

Also Published As

Publication number Publication date
TW593249B (en) 2004-06-21
US6423729B1 (en) 2002-07-23
EP1398027B1 (de) 2007-01-10
NO20000285L (no) 2000-03-22
AU8243998A (en) 1999-02-16
HUP0003851A3 (en) 2002-10-28
ID24105A (id) 2000-07-06
US20030078434A1 (en) 2003-04-24
SK262000A3 (en) 2001-01-18
TW200400934A (en) 2004-01-16
ID29293A (id) 1999-01-28
CA2297011A1 (en) 1999-02-04
BR9811521A (pt) 2000-08-22
CN1270518A (zh) 2000-10-18
KR20010022106A (ko) 2001-03-15
JP3621427B2 (ja) 2005-02-16
RU2207849C2 (ru) 2003-07-10
KR100386148B1 (ko) 2003-06-02
WO1999004780A1 (en) 1999-02-04
US6878739B2 (en) 2005-04-12
AU737218B2 (en) 2001-08-09
IL133933A0 (en) 2001-04-30
CA2297011C (en) 2007-01-30
NZ502274A (en) 2001-03-30
EP1029541A1 (de) 2000-08-23
TR200100389T2 (tr) 2001-08-21
TR200000214T2 (tr) 2000-09-21
HUP0003851A2 (hu) 2001-07-30
DE69833940D1 (de) 2006-05-11
TWI249518B (en) 2006-02-21
EP1029541A4 (de) 2000-08-23
PL338235A1 (en) 2000-10-09
EP1398027A1 (de) 2004-03-17
DE69833940T2 (de) 2006-12-14
CN1198607C (zh) 2005-04-27
DE69836877D1 (de) 2007-02-22
NO20000285D0 (no) 2000-01-20
EP1029541B1 (de) 2006-03-22

Similar Documents

Publication Publication Date Title
ATE320801T1 (de) Therapeutisches oder vorbeugendes mittel für glomerulopathie
MY128113A (en) Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
ATE369337T1 (de) Neue bizyklische verbindungen
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
ZA200409618B (en) Pyrazolopyrimidines and the use thereof controlling harmful organisms.
DK0920430T3 (da) Purinderivater og deres anvendelse som antikoaguleringsmidler
HUT43238A (en) Herbicidal compositions comprising substituted piridine-sulfonamide derivatives as active substance and process for preparing the active substances
ATE274521T1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
ATE271868T1 (de) Neue cathechole als antimikrobielle mittel
ATE438629T1 (de) Mittel, die vorbeugend bzw. heilend bei alzheimer-krankheit wirken, oder inhibitoren der fibrose von amyloiden proteinen, enthaltend stickstoffhaltige heteroarylverbindungen
ES2180201T3 (es) Derivados de azetidinona para el tratamiento de infecciones por hcmv.
ES2130258T3 (es) Compuesto amino terciario sustituido o sal de este compuesto.
DE60005689D1 (de) Neue aminobenzophenone
EP1252890A4 (de) Heilmittel und vorbeugende mittel für verdauungserkrankungen die diaminotrifluoromethylpyridinverbindungen enthalten
PT1709027E (pt) Compostos do tipo hidrazida e sua utilização em composições farmacêuticas para o tratamento de doenças cardiovasculares
DE69811689D1 (de) Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
EP1256581A4 (de) Vorbeugende oder therapeutische mittel für gastriche oder ösophageale regurgitation
ATE274508T1 (de) Aminophenolderivate
WO2003043582A3 (en) Modulators of rho c activity
RU2002101136A (ru) Средства для лечения и профилактики неоплазм
BR9916366A (pt) Derivados de 6-azauracila, inibidores de il-5
WO2002088091A3 (en) Inhibitors of human rhinovirus 2a cysteine protease
DE60208554D1 (de) Neue aliphatische verbindung, syntheseverfahren und anwendungsverfahren
NO20051774L (no) Taksanderivater funksjonalisert pa den 14.posisjon og en fremgangsmate for fremstilling derav
ATE223406T1 (de) 1,4-disubstitutierte cyclohexanderivate zur behandlung von depression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties